WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides

American Journal of Hematology

Volumn 90, Issue 7, 2015, Pages 602-607

  Brayer, Jason ^a   Lancet, Jeffrey E ^a,b   Powers, John ^a   List, Alan ^a,b   Balducci, Lodovico ^a,b   Komrokji, Rami ^a,b   Pinilla Ibarz, Javier ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; PEPTIDE VACCINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; WILMS TUMOR 1 VACCINE; WT1 PROTEIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGIC FACTOR; PEPTIDE; RECOMBINANT PROTEIN; SARGRAMOSTIM; SUBUNIT VACCINE; WT1 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; AGED; ARTICLE; BLOATING; CANCER FATIGUE; CANCER IMMUNIZATION; CANCER PAIN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; IMMUNOGENICITY; INJECTION SITE REACTION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKEMIA REMISSION; LEUKOPENIA; MALE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; TREATMENT DURATION; WEAKNESS; BIOSYNTHESIS; CHEMISTRY; CLINICAL TRIAL; GENE EXPRESSION; GENETICS; HYPERSENSITIVITY, DELAYED; IMMUNIZATION; IMMUNOLOGY; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MORTALITY; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; REMISSION; SURVIVAL; SYNTHESIS; VACCINATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CANCER VACCINES; FEMALE; GENE EXPRESSION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNIZATION, SECONDARY; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; PEPTIDES; PILOT PROJECTS; RECOMBINANT PROTEINS; REMISSION INDUCTION; SURVIVAL ANALYSIS; VACCINATION; VACCINES, SUBUNIT; WT1 PROTEINS;

EID: 84931957457     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24014     Document Type: Article

References (27)

1. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a cd8(+) cytotoxic T-lymphocyte clone specific for wt1 peptide. Blood 2000;95:286-293.
2. Oka Y, Tsuboi A, Taguchi T, et al. Induction of wt1 (wilms' tumor gene)-specific cytotoxic T lymphocytes by wt1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004;101:13885-13890.
3. Pinilla-Ibarz J, May RJ, Korontsvit T, et al. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the wt1 oncoprotein. Leukemia 2006;20:2025-2033.
4. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined pr1 and wt1 peptide vaccination in patients with myeloid malignancies. Blood 2008;111:236-242.
5. Miwa H, Beran M, Saunders GF. Expression of the wilms' tumor gene (wt1) in human leukemias. Leukemia 1992;6:405-409.
6. Bergmann L, Miething C, Maurer U, et al. High levels of wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997;90:1217-1225.
7. Kim SC, Yoo NC, Hahn JS, et al. Monitoring of WT-1 gene expression in peripheral blood of patients with acute leukemia by semiquantitative RT-PCR; possible marker for detection of minimal residual leukemia. Yonsei Med J 1997;38:212-219.
8. Virappane P, Gale R, Hills R, et al. Mutation of the wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom medical research council adult leukaemia working party. J Clin Oncol 2008;26:5429-5435.
9. Paschka P, Marcucci G, Ruppert AS, et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J Clin Oncol 2008;26:4595-4602.
10. Ernst T, Chase A, Zoi K, et al. Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica 2010;95:1473-1480.
11. Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type wilms' tumor gene (wt1) product. Immunogenetics 2000;51:99-107.
12. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic cd34(+) progenitor cells by cytotoxic T lymphocytes specific for wt1. Blood 2000;95:2198-2203.
13. Doubrovina E, Carpenter T, Pankov D, et al. Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias. Blood 2012;120:1633-1646.
14. Bellantuono I, Gao L, Parry S, et al. Two distinct HLA-A0201-presented epitopes of the wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 2002;100:3835-3837.
15. Tsuboi A, Oka Y, Udaka K, et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer wt1 peptide modified at HLA-a*2402-binding residues. Cancer Immunol Immunother 2002;51:614-620.
16. Rezvani K, Yong AS, Mielke S, et al. Repeated pr1 and wt1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific cd8+ T cells in myeloid malignancies. Haematologica 2011;96:432-440.
17. Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in cd8+ T lymphocytes. Nature 2003;421:852-856.
18. May RJ, Dao T, Pinilla-Ibarz J, et al. Peptide epitopes from the wilms' tumor 1 oncoprotein stimulate cd4+ and cd8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 2007;13:4547-4555.
19. Willasch AM, Gruhn B, Coliva T, et al. Standardization of wt1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of wt1 gene mutations: A European multicenter study. Leukemia 2009;23:1472-1479.
20. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-425.
21. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-4649.
22. Maslak PG, Dao T, Krug LM, et al. Vaccination with synthetic analog peptides derived from wt1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010;116:171-179.
23. Uttenthal B, Martinez-Davila I, Ivey A, et al. Wilms' tumour 1 (wt1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. Br J Haematol 2014;164:366-375.
24. Shedlock DJ, Shen H. Requirement for cd4 T cell help in generating functional cd8 T cell memory. Science 2003;300:337-339.
25. Bevan MJ. Helping the cd8(+) T-cell response. Nat Rev Immunol 2004;4:595-602.
26. Fuller MJ, Hildeman DA, Sabbaj S, et al. Cutting edge: emergence of CD127high functionally competent memory T cells is compromised by high viral loads and inadequate T cell help. J Immunol 2005;174:5926-5930.
27. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-422.